Sacklers call opioid-related fraud claims ‘utterly meritless’

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Does visual impairment influence mental disorders?

Whether visual impairment (VI) affects mental disorders in the older population.

January 31, 2024

SNDL Buys Indiva Assets

SNDL Emerges as Canada’s Leading Producer of Edibles with Indiva Acquisition CALGARY, AB, Nov. 4, 2024 /CNW/ – SNDL Inc. (Nasdaq: SNDL) (“SNDL” or the

November 5, 2024

Mark Cuban’s Cost Plus Drug Company adds new SGLT2 inhibitor Brenzavvy for type 2 diabetes

Mark Cuban’s Cost Plus Drug Company is bringing another brand-name type 2 diabetes treatment under its wing. TheracosBio’s recently approved SGLT2 inhibitor Brenzavvy is now

July 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.